. Amit Kumar Singh; . Sonali Jain; . Dinesh Kumar; . Ravinder Pal Singh; . Hitesh Bhatt
Volume 4, Issue 3 , July 2015, , Pages 153-159
Abstract
Objective: There is an increased prevalence of extended‑spectrum beta‑lactamase producing Klebsiella pneumoniae (ESBL‑KP) worldwide including India, which is a major concern for ...
Read More
Objective: There is an increased prevalence of extended‑spectrum beta‑lactamase producing Klebsiella pneumoniae (ESBL‑KP) worldwide including India, which is a major concern for the clinicians, especially in intensive care units and pediatric patients. This study aims to determine the prevalence of ESBL‑KP and antimicrobial sensitivity profile to plan a proper hospital infection control program to prevent the spread of resistant strains.Methods: KP isolates obtained from various clinical samples were evaluated to detect the production of ESBL by phenotypic methods. Antimicrobial susceptibility profile was also determined of all the isolates.Findings: Of 223 nonduplicate isolates of K. pneumoniae, 114 (51.1%) were ESBL producer and antimicrobial susceptibility profile showed the isolates were uniformly sensitive to imipenem and highly susceptible to beta‑lactamase inhibitor combination drugs(67–81%) and aminoglycosides (62–76%), but less susceptible to third generation cephalosporins (14–24%) and non‑β‑lactam antibiotics such as nitrofurantoin (57%), fluoroquinolones (29–57%), piperacillin (19–23%), and aztreonam (15–24%).Conclusion: This study found that beta‑lactamase inhibitor combinations are effective in treatment of such infections due to ESBL‑KP thus these drugs should be a part of the empirical therapy and carbapenems should be used when the antimicrobial susceptibility tests report resistance against inhibitors combinations.
